Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26095814 | 1.00 | TRPV4 (0.38) | TRPV4HPGDSMN1; SMN2ROCK1 | |
| SCHEMBL27031413 | 0.76 | TRPV4 (0.39) | TRPV4HPGDSMN1; SMN2 | |
| SCHEMBL30296304 | 0.76 | TRPV4 (0.39) | TRPV4HPGDSMN1; SMN2 | |
| SCHEMBL30296471 | 0.74 | HPGD (0.31) | TRPV4HPGDSMN1; SMN2 | |
| SCHEMBL25407825 | 0.69 | HPGD (0.41) | HPGDSMN1; SMN2 | |
| SCHEMBL31322429 | 0.69 | TDP1 (0.41) | TRPV4 | |
| SCHEMBL31348088 | 0.68 | TRPV4 (0.53) | TRPV4SMN1; SMN2 | |
| SCHEMBL21225855 | 0.68 | TRPV4 (0.53) | TRPV4SMN1; SMN2 | |
| SCHEMBL24713234 | 0.68 | TRPV4 (0.38) | TRPV4 | |
| SCHEMBL28824722 | 0.67 | TRPV4 (0.47) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | TRPV4 542/4885HPGD 1613/4885SMN1; SMN2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.